FDA Approves Celcuity's Breast Cancer Drug

The U.S. Food and Drug Administration (FDA) has approved a new drug developed by biotechnology company Celcuity for the treatment of advanced breast cancer. This marks the company's first product to reach the market. In clinical trials, the drug was observed to reduce the risk of disease progression by 76%. This result is considered a significant success in terms of treatment efficacy. Following the approval news, Celcuity shares traded on the Nasdaq experienced a notable rise. Investors responded positively to the drug's commercial potential. This is not investment advice.

📊 CELH — Piyasa Yorumu

▲ up · 70%

FDA approval serves as a significant catalyst for CELH, potentially triggering a short-term upward move in the stock. While technical indicators present a neutral picture, the RSI at 47 is not in oversold territory, and the MACD is above its signal line, suggesting momentum could turn positive. The price sitting just above the 20-day SMA indicates it has tested a support level and may see buying interest. However, remaining below the 50-day SMA warns that any upside may be limited. Buying pressure from the news could drive a move toward the resistance zone around $31 in the near term.

RSI 14

47.1

MACD

-0.23

24h Δ

-0.64%

Canlı Grafikler